Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.

Our results indicate that tofacitinib may be as effective as or even better than intensive conventional immunosuppressants, with a quicker and higher response rate in refractory dcSSc patients with progressive skin thickness.